IDHIFA® - for Acute Myeloid Leukemia
IDHIFA® (Enasidenib) for Acute Myeloid Leukemia (AML) with IDH2 mutation
Select patients for the treatment of AML with IDHIFA® based on the presence of IDH2 mutations in the blood or bone marrow. Monitor patients closely for symptoms of differentiation syndrome, leukocytosis, elevated bilirubin and GI toxicities. Monitor at a minimum of every 2 weeks for at least the first 3 months during treatment. Treatment continued until disease progression or unacceptable toxicity. In the absence of disease progression or unacceptable toxicity, treatment for a minimum of 6 months is recommended to allow time for a clinical response.
Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration
IDHIFA® (Enasidenib) PO 100 mg Daily N/A N/A N/A N/A